دورية أكاديمية
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.
| العنوان: | A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis. |
|---|---|
| المؤلفون: | Mascarenhas J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Migliaccio AR; Altius Institute for Biomedical Sciences, Seattle, Washington., Kosiorek H; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona., Bhave R; Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina., Palmer J; Mayo Clinic Scottsdale, Arizona., Kuykendall A; Department of Hematologic Malignancy, Moffitt Cancer Center, Tampa, Florida., Mesa R; Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina., Rampal RK; Leukemia Service, Department of Medicine, Center for Hematologic Malignancies, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York., Gerds AT; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio., Yacoub A; The University of Kansas Cancer Center, Westwood, Kansas., Pettit K; University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan., Talpaz M; University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan., Komrokji R; Department of Hematologic Malignancy, Moffitt Cancer Center, Tampa, Florida., Kremyanskaya M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Gonzalez A; The University of Texas Health Science Center at San Antonio, San Antonio, Texas., Fabris F; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Johnson K; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Dougherty M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., McGovern E; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York., Arango Ossa J; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York., Domenico D; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York., Farnoud N; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York., Weinberg RS; New York Blood Center, New York, New York., Kong A; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Najfeld V; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Vannucchi AM; University of Florence, Azienda Ospedaliero Universitaria Careggi, Florence, Italy., Arciprete F; Unit of Microscopic and Ultrastructural Anatomy, University Campus Bio-Medico, Rome, Italy., Zingariello M; Unit of Microscopic and Ultrastructural Anatomy, University Campus Bio-Medico, Rome, Italy., Falchi M; National HIV/AIDS Research Center, Istituto Superiore di Sanità, Viale Regina Elena Rome Italy., Salama ME; Sonic Healthcare, Austin, Texas., Mead-Harvey C; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona., Dueck A; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona., Varricchio L; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Hoffman R; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Sep 15; Vol. 29 (18), pp. 3622-3632. |
| نوع المنشور: | Clinical Trial, Phase I; Multicenter Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Denville, NJ : The Association, c1995- |
| مواضيع طبية MeSH: | Primary Myelofibrosis*/drug therapy , Primary Myelofibrosis*/metabolism , Myeloproliferative Disorders* , Thrombocytopenia*/chemically induced, Humans ; Janus Kinase 2/metabolism ; Cytokines/therapeutic use ; Immunologic Factors/therapeutic use |
| مستخلص: | Purpose: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by systemic symptoms, cytopenias, organomegaly, and bone marrow fibrosis. JAK2 inhibitors afford symptom and spleen burden reduction but do not alter the disease course and frequently lead to thrombocytopenia. TGFβ, a pleiotropic cytokine elaborated by the MF clone, negatively regulates normal hematopoiesis, downregulates antitumor immunity, and promotes bone marrow fibrosis. Our group previously showed that AVID200, a potent and selective TGFβ 1/3 trap, reduced TGFβ1-induced proliferation of human mesenchymal stromal cells, phosphorylation of SMAD2, and collagen expression. Moreover, treatment of MF mononuclear cells with AVID200 led to increased numbers of progenitor cells (PC) with wild-type JAK2 rather than JAK2V617F. Patients and Methods: We conducted an investigator-initiated, multicenter, phase Ib trial of AVID200 monotherapy in 21 patients with advanced MF. Results: No dose-limiting toxicity was identified at the three dose levels tested, and grade 3/4 anemia and thrombocytopenia occurred in 28.6% and 19.0% of treated patients, respectively. After six cycles of therapy, two patients attained a clinical benefit by IWG-MRT criteria. Spleen and symptom benefits were observed across treatment cycles. Unlike other MF-directed therapies, increases in platelet counts were noted in 81% of treated patients with three patients achieving normalization. Treatment with AVID200 resulted in potent suppression of plasma TGFβ1 levels and pSMAD2 in MF cells. Conclusions: AVID200 is a well-tolerated, rational, therapeutic agent for the treatment of patients with MF and should be evaluated further in patients with thrombocytopenic MF in combination with agents that target aberrant MF intracellular signaling pathways. (©2023 The Authors; Published by the American Association for Cancer Research.) |
| References: | Nature. 2018 Feb 22;554(7693):544-548. (PMID: 29443960) Clin Trials. 2010 Dec;7(6):653-63. (PMID: 20935021) Leukemia. 2021 Oct;35(10):2875-2884. (PMID: 34480104) Blood. 2010 Mar 4;115(9):1703-8. (PMID: 20008785) Curr Hematol Malig Rep. 2022 Oct;17(5):140-154. (PMID: 35984598) J Clin Invest. 2022 Jun 1;132(11):. (PMID: 35439167) Leukemia. 2023 Feb;37(2):255-264. (PMID: 36434065) Neuro Oncol. 2016 Aug;18(8):1146-56. (PMID: 26902851) Blood. 2013 Aug 22;122(8):1395-8. (PMID: 23838352) J Clin Invest. 2019 Mar 4;129(4):1596-1611. (PMID: 30730307) Cancer Chemother Pharmacol. 2015 Dec;76(6):1143-52. (PMID: 26526984) Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):415-421. (PMID: 32199764) Cancer Chemother Pharmacol. 2019 May;83(5):975-991. (PMID: 30887178) Growth Factors. 2015 Apr;33(2):79-91. (PMID: 25586866) Oncologist. 2023 Feb 8;28(2):e124-e127. (PMID: 36576431) Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78. (PMID: 11252892) Nat Biotechnol. 2013 Mar;31(3):213-9. (PMID: 23396013) Leuk Lymphoma. 2014 Feb;55(2):450-2. (PMID: 23682558) Genome Biol. 2016 Jun 06;17(1):122. (PMID: 27268795) Biomarkers. 2007 May-Jun;12(3):313-30. (PMID: 17453744) JCO Precis Oncol. 2017 Jul;2017:. (PMID: 28890946) Blood. 2010 Jan 21;115(3):453-74. (PMID: 19880497) J Pharmacol Exp Ther. 2005 Dec;315(3):1005-12. (PMID: 16120811) Oncologist. 2023 Mar 17;28(3):258-267. (PMID: 36571770) BMJ Open Respir Res. 2022 Jan;9(1):. (PMID: 35058236) Mol Oncol. 2022 Jun;16(11):2117-2134. (PMID: 34854206) J Exp Med. 2016 Aug 22;213(9):1723-40. (PMID: 27481130) Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):453-462. (PMID: 34889421) Blood. 2009 Feb 5;113(6):1250-6. (PMID: 18945958) J Med Chem. 2021 Dec 23;64(24):18193-18208. (PMID: 34894681) Clin Cancer Res. 2019 Dec 1;25(23):6976-6985. (PMID: 31481511) Sci Transl Med. 2016 Mar 2;8(328):328ra30. (PMID: 26936507) Mol Cancer Ther. 2021 Feb;20(2):389-397. (PMID: 33268571) Exp Hematol. 2019 Nov;79:16-25.e3. (PMID: 31678370) Br J Haematol. 1988 Oct;70(2):143-7. (PMID: 3191027) J Cardiovasc Dev Dis. 2021 Mar 02;8(3):. (PMID: 33801433) Bioinformatics. 2012 Jul 15;28(14):1838-44. (PMID: 22569178) JAMA Oncol. 2018 Dec 1;4(12):1787. (PMID: 30422175) Cancer. 2022 Jul 15;128(14):2717-2727. (PMID: 35385124) Haematologica. 2005 Aug;90(8):1128-32. (PMID: 16079113) Blood. 2005 May 1;105(9):3493-501. (PMID: 15665119) Blood. 2002 Nov 15;100(10):3495-503. (PMID: 12393681) Exp Hematol. 2016 Dec;44(12):1138-1155.e4. (PMID: 27592389) Blood. 2000 Sep 15;96(6):2022-36. (PMID: 10979943) Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e507-e520. (PMID: 35221248) Blood. 2015 Jun 4;125(23):3542-50. (PMID: 25833962) Cytokine Growth Factor Rev. 2013 Apr;24(2):133-45. (PMID: 23415024) Bioinformatics. 2009 Nov 1;25(21):2865-71. (PMID: 19561018) JCI Insight. 2021 Sep 22;6(18):. (PMID: 34383713) Cancer Chemother Pharmacol. 2017 Jun;79(6):1169-1177. (PMID: 28451833) Cancer Res. 2011 Apr 15;71(8):2901-15. (PMID: 21487043) Cancer Immunol Res. 2019 Feb;7(2):306-320. (PMID: 30538091) Cancer Res. 2015 Nov 15;75(22):4753-65. (PMID: 26404004) Stem Cells. 2000;18(2):102-11. (PMID: 10742382) Eur J Pharmacol. 2015 Dec 15;769:134-42. (PMID: 26548624) Bioinformatics. 2012 Jul 15;28(14):1811-7. (PMID: 22581179) Haematologica. 2016 Jun;101(6):660-71. (PMID: 27252511) Cancer Med. 2021 May;10(9):3059-3067. (PMID: 33811482) Blood. 2007 Aug 1;110(3):986-93. (PMID: 17473062) J Biol Chem. 2002 Nov 1;277(44):41361-8. (PMID: 12193595) Bioanalysis. 2017 Apr;9(8):621-630. (PMID: 28504552) |
| معلومات مُعتمدة: | P01 CA108671 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS; P30 CA196521 United States CA NCI NIH HHS |
| المشرفين على المادة: | EC 2.7.10.2 (Janus Kinase 2) 0 (Cytokines) 0 (Immunologic Factors) |
| تواريخ الأحداث: | Date Created: 20230713 Date Completed: 20230918 Latest Revision: 20231121 |
| رمز التحديث: | 20231121 |
| مُعرف محوري في PubMed: | PMC10502472 |
| DOI: | 10.1158/1078-0432.CCR-23-0276 |
| PMID: | 37439808 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-3265 |
|---|---|
| DOI: | 10.1158/1078-0432.CCR-23-0276 |